GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Wallentin, Lars ^a   Zethelius, Björn ^a   Berglund, Lars ^a   Eggers, Kai M ^a   Lind, Lars ^a   Lindahl, Bertil ^a   Wollert, Kai C ^b   Siegbahn, Agneta ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; GROWTH DIFFERENTIATION FACTOR 15; TROPONIN T;

AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PROGNOSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PROGNOSIS; PROTEIN BLOOD LEVEL; SMOKING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891607853     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078797     Document Type: Article

References (45)

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z et al. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 33: 1635-1701. doi:10.1093/eurheartj/ehs092. PubMed: 22555213.
2. Romaguera D, Vergnaud AC, Peeters PH, van Gils CH, Chan DS et al. (2012) Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. Am J Clin Nutr 96: 150-163. doi:10.3945/ajcn.111. 031674. PubMed: 22592101.
3. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358: 2107-2116. doi: 10.1056/NEJMoa0707064. PubMed: 18480203.
4. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F et al. (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121: 2388-2397. doi:10.1161/ CIRCULATIONAHA.109.901413. PubMed: 20497981.
5. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS et al. (2011) Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 123: 1367-1376. doi:10.1161/CIRCULATIONAHA.110.005264. PubMed: 21422391.
6. Xu R, Ye P, Luo L, Xiao W, Sheng L et al. (2011) Association between high-sensitivity cardiac troponin T and predicted cardiovascular risks in a community-based population. Int J Cardiol 149: 253-256. doi: 10.1016/j.ijcard.2011.02.032. PubMed: 21388695.
7. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG et al. (2011) The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29: 187-195. doi:10.3109/08977194.2011.607137. PubMed: 21831009.
8. Wollert KC, Kempf T (2012) Growth Differentiation Factor 15 in Heart Failure: An. Update - Curr Heart Fail Rep 9: 337-345. doi:10.1007/ s11897-012-0113-9.
9. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M et al. (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50: 1054-1060. doi:10.1016/j.jacc.2007.04.091. PubMed: 17825714.
10. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T et al. (2007) Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53: 284-291. PubMed: 17185363.
11. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C et al. (2006) The transforming growth factor-beta superfamily member growthdifferentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98: 351-360. doi:10.1161/01.RES. 0000202805.73038.48. PubMed: 16397141.
12. Kempf T, Wollert KC (2009) Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 34: 594-599. doi:10.1007/s00059-009- 3317-3. PubMed: 20024638.
13. Lind L, Wallentin L, Kempf T, Tapken H, Quint A et al. (2009) Growthdifferentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 30: 2346-2353. doi:10.1093/eurheartj/ehp261. PubMed: 19561023.
14. Eggers KM, Kempf T, Lind L, Sundström J, Wallentin L et al. (2012) Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 72: 45-51. doi: 10.3109/00365513.2011.626072. PubMed: 22023041.
15. Wollert KC, Kempf T, Peter T, Olofsson S, James S et al. (2007) Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115: 962-971. doi: 10.1161/CIRCULATIONAHA.106.650846. PubMed: 17283261.
16. Eggers KM, Kempf T, Allhoff T, Lindahl B, Wallentin L et al. (2008) Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J 29: 2327-2335. doi:10.1093/eurheartj/ehn339. PubMed: 18664460.
17. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S et al. (2010) Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 3: 88-96. doi:10.1161/CIRCGENETICS.109.877456. PubMed: 20160200.
18. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T et al. (2010) Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122: 1387-1395. doi:10.1161/CIRCULATIONAHA. 109.928846. PubMed: 20855664.
19. Brown DA, Hance KW, Rogers CJ, Sansbury LB, Albert PS et al. (2012) Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? Cancer Epidemiol Biomarkers Prev 21: 337-346. doi: 10.1158/1055-9965.EPI-11-0786. PubMed: 22144502.
20. Wallin U, Glimelius B, Jirström K, Darmanis S, Nong RY et al. (2011) Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer 104: 1619-1627. doi:10.1038/bjc.2011.112. PubMed: 21468045.
21. Corre J, Labat E, Espagnolle N, Hébraud B, Avet-Loiseau H et al. (2012) Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res 72: 1395-1406. doi: 10.1158/1538-7445.AM2012-1395. PubMed: 22301101.
22. Brown DA, Lindmark F, Stattin P, Bälter K, Adami HO et al. (2009) Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 15: 6658-6664. doi: 10.1158/1078-0432.CCR-08-3126. PubMed: 19843661.
23. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC et al. (2010) Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 118: 237-243. doi:10.1016/j.ygyno.2010.05.032. PubMed: 20576287.
24. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE et al. (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9: 2642-2650. PubMed: 12855642.
25. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T et al. (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 100: 3410-3415. doi:10.1073/pnas.0530278100. PubMed: 12624183.
26. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F et al. (2010) Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 9: 1057-1064. doi:10.1111/j.1474-9726.2010.00629.x. PubMed: 20854422.
27. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E (2011) Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 123: 2101-2110. doi:10.1161/CIRCULATIONAHA.110.979740. PubMed: 21536998.
28. Rohatgi A, Patel P, Das SR, Ayers CR, Khera A et al. (2012) Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem 58: 172-182. doi: 10.1373/clinchem.2011.171926. PubMed: 22065155.
29. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR et al. (2002) Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 359: 2159-2163. doi:10.1016/S0140-6736(02)09093-1. PubMed: 12090982.
30. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL et al. (2012) Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation 126: 1596-1604. doi:10.1161/CIRCULATIONAHA.112.129437. PubMed: 22907935.
31. Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23: 2109-2123. doi:10.1002/sim.1802. PubMed: 15211606.
32. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-212; discussion: 17569110.
33. Pencina MJ, D'Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30: 11-21. doi:10.1002/sim.4085. PubMed: 21204120.
34. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612. doi: 10.1016/S0140-6736(11) 61720-0. PubMed: 22440946.
35. Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol. 6: 140-146. doi:10.1016/j.molonc.2012.01.010. PubMed: 22356776.
36. Verma M (2012) Epigenetic biomarkers in cancer epidemiology. Methods Mol Biol 863: 467-480. doi:10.1007/978-1-61779-612-8-28. PubMed: 22359311.
37. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL et al. (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-2060. doi:10.1056/NEJMoa043161. PubMed: 15901858.
38. Wu CK, Lin JW, Caffrey JL, Chang MH, Hwang J.Jet al (2010) Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (Third National Health and Nutrition Examination Survey). J Am Coll Cardiol 56:1930-6
39. Jobs E, Ingelsson E, Risérus U, Nerpin E, Jobs M et al. (2011) Association between serum cathepsin S and mortality in older adults. JAMA 306: 1113-1121. doi:10.1001/jama.2011.1246. PubMed: 21878432.
40. Xu X, Li Z, Gao W (2011) Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers 16: 466-475. doi:10.3109/1354750X.2011.580006. PubMed: 21718220.
41. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT (2003) Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2: 1023-1029. PubMed: 14578467.
42. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A et al. (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17: 581-588. doi: 10.1038/nm.2354. PubMed: 21516086.
43. de Jager SC, Bermúdez B, Bot I, Koenen RR, Bot M et al. (2011) Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. J Exp Med 208: 217-225. doi:10.1084/jem.20100370. PubMed: 21242297.
44. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W et al. (2004) Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 318: 325-333. doi:10.1007/s00441-004-0986-3. PubMed: 15459768.
45. Mimeault M, Batra SK (2010) Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 224: 626-635. doi:10.1002/jcp.22196. PubMed: 20578239.